This finding matters because people with HIV often face faster biological aging and higher rates of age-related conditions. If a drug already approved for metabolic conditions can alter aging markers, it opens a path to therapies that help people stay healthier for longer. The results are early and the study group was small, so researchers emphasize the need for larger, longer trials before drawing firm conclusions.
Curious about how a medication tied to appetite and metabolism might touch the biology of aging? The full article walks through the study’s design, the specific biomarkers measured, and what questions remain for scientists focused on extending healthy lifespan and making treatments equitable for those most at risk.
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging. Although the findings are encouraging, scientists say larger studies are needed before concluding that the medication can help people age more slowly.
